A Phase 3 interventional study of Integrative Care in Lung Neoplasms, Esophageal Neoplasms and Stomach Neoplasms, sponsored by The Canadian College of Naturopathic Medicine. Completed at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-20.
Sponsored by The Canadian College of Naturopathic Medicine · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 383 studies in Lung Neoplasms with a site in Canada — 66 open to participants now, 99 under way, 26 of them phase 3. Lung Neoplasms · Canada.
Among the 383 studies in Lung Neoplasms with a site in Canada, this one is the 268th largest by enrollment of the 315 interventional ones that give a count, is one of 16 that started in 2018, is one of 77 in phase 3, and was the 219th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →66 of the 383 studies in Lung Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+
SystImmune Inc. · Sites in Canada, United States, Australia and 13 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Canada, United States, Belgium and 10 more countries
Ages 18+
University of British Columbia · Sites in Canada
Ages 19–80 · Healthy volunteers
University Health Network, Toronto · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
383 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 77 · Phase 2 117 · Phase 3 86 · Phase 4 4
First in 1994; this study’s year is marked. 16 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 100 across the 315 interventional studies, 137 across the 56 observational. Of the 253 that completed or were terminated, 64 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
139 of 383 have an industry lead sponsor. The 10 most frequent:
The Canadian College of Naturopathic Medicine is the lead sponsor of 19 studies on the registry; 1 is open to participants now.
The Canadian College of Naturopathic Medicine has 3 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
29 of the studies in Lung Neoplasms with a site in Canada that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04093167Phase 3Canadian Cancer Trials GroupStudy of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer | 2026-12-31 |
| NCT04380636Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | 2027-05-05 |
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06635824Phase 3GenmabTrial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | 2027-07-30 |
| NCT03793179Phase 3National Cancer Institute (NCI)Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | 2027-09-30 |
Add all 29 to your calendar (.ics) → With an account.
Among the 383 studies in Lung Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Stage I of the Thoracic-POISE study will pilot-test a broad-based, multi-agent integrative care intervention delivered by naturopathic doctors in conjunction with standard surgical and oncologic care of people with thoracic cancer.
Despite enormous advances in thoracic surgery and oncology, two critical issues concern patients undergoing curative-intent surgery for lung, gastric and esophageal cancer: first, a majority (\~60%) of patients experience minor and major adverse events occurring during and in the days following surgery; second, patients worry about the significant risk of cancer recurrence and mortality months to years after surgery. These issues, combined with side effects of chemotherapy and radiation, have detrimental effects on health-related quality of life (HRQoL). On a deeper level, there is the problem of an ongoing failure to integrate and evaluate the best of what complementary medicine has to offer surgical oncology care.
The Thoracic-POISE Project has the overarching goal of improving care for thoracic cancer patients by impacting HRQoL, reducing surgical adverse events, prolonging overall survival and pioneering integrative care delivery. This multi-stage project aims to design, pilot-test and evaluate a broad-based, multi-agent, evidence-based integrative care program to be delivered by naturopathic doctors (ND) in conjunction with standard surgical and oncologic care. It is hypothesized that this integrative care program will improve HRQoL as well as reduce surgical adverse events and improve cancer survival. Stage I of the project will pilot-test the intervention and outcomes collection in a single-arm, feasibility study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Broad-based, multi-agent integrative care program delivered by naturopathic doctors (ND) in conjunction with standard surgical and oncologic care.
Other: Integrative Care
Standardized supplemental/natural health product, physical, nutritional and mental/emotional recommendations based on the phases of standard care (neo-adjuvant, perioperative, adjuvant and long-term maintenance).
Feasibility of study protocol
Percentage of participants who complete all assessments and integrative care appointments
Time frame: Enrollment - 1 year post surgery
Compliance: supplemental intervention
Count of missed doses assessed by patient diary.
Time frame: Enrollment - 1 year post surgery
Compliance: nutritional intervention
Mediterranean diet score calculated by food frequency questionnaire administered at enrollment and 1 year post surgery
Time frame: Enrollment - 1 year post surgery
Compliance: physical intervention
Extent of adherence to physical activity recommendations assessed using a patient diary.
Time frame: Enrollment - 1 year post surgery
Compliance: mental/emotional domain
Number of days audio-recordings were used assessed by patient diary.
Time frame: Enrollment - 1 year post surgery
Communication between practitioners
Number of communications (phone, consult note, etc.) between integrative and standard care practitioners per participant
Time frame: Enrollment - 1 year post surgery
Qualitative experience of care and study protocol
Semi-structured interviews with thematic analysis
Time frame: Enrollment - 1 year post surgery
Feasibility of recruitment
Percentage of participants recruited out of potentially eligible patients invited.
Time frame: Enrollment
Adverse events
Collection of adverse events related to surgery, adjuvant therapy, and the interventions
Time frame: Enrollment - 1 year post surgery
Health Related Quality of Life
Functional Assessment of Cancer Therapy-General Score
Time frame: Enrollment - 1 year post surgery
Cancer-related symptoms
Edmonton Symptom Assessment Scale
Time frame: Enrollment - 1 year post surgery
Anxiety and Depression
Hospital Anxiety and Depression Scale
Time frame: Enrollment - 1 year post surgery
Fatigue
Multidimensional Fatigue Inventory
Time frame: Enrollment - 1 year post surgery
Functional exercise capacity
6 minute walk test
Time frame: Enrollment - 1 year post surgery
Inflammation: Multi-analyte cytokine array.
Plasma concentrations of a panel of cytokines (IL2, IL10, TGF-beta, TNF-alpha, IFN-alpha, and IFN-gamma) will be measured in blood samples collected 4 weeks before surgery, 2-3 days before surgery, on post-operative day (POD) 1, POD 5 (+/-2), 3-4 weeks, 6 months and 1 year post-surgery
Time frame: Enrollment - 1 year post surgery
Natural kill cell activation
NK cell activity will be measured by NKVue™ in blood samples collected 4 weeks before surgery, 2-3 days before surgery, on post-operative day (POD) 1, POD 5 (+/-2), 3-4 weeks, 6 months and 1 year post-surgery
Time frame: Enrollment - 1 year post surgery
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2018 to primary completion in Dec 2020, 23 months.
Of 65 non-industry phase 3 interventional studies under Lung Neoplasms, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 99. This study's 23 months is below that.
Counting every sponsor, half of 127 studies reached it within 43 months; a quarter within 30 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Canadian College of Naturopathic Medicine